H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia

[1]  J. Qian,et al.  Hypomethylation‐mediated H19 overexpression increases the risk of disease evolution through the association with BCR‐ABL transcript in chronic myeloid leukemia , 2018, Journal of cellular physiology.

[2]  J. Qian,et al.  Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression , 2018, Oncogene.

[3]  Wei Zhang,et al.  LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. , 2017, Molecular medicine reports.

[4]  Wei Zhang,et al.  High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia , 2017, Oncotarget.

[5]  J. Qian,et al.  Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[6]  J. Qian,et al.  Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies , 2017, Journal of cellular and molecular medicine.

[7]  Kankan Wang,et al.  Long noncoding RNAs: pivotal regulators in acute myeloid leukemia , 2016, Experimental Hematology & Oncology.

[8]  Cheng Qiu,et al.  Prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: evidence from a meta-analysis , 2016, Oncotarget.

[9]  C. Mason,et al.  Genetic and epigenetic heterogeneity in acute myeloid leukemia. , 2016, Current opinion in genetics & development.

[10]  J. Qian,et al.  The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia , 2016, Tumor Biology.

[11]  A. Hochberg,et al.  The H19 Long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory , 2015, Molecular Cancer.

[12]  J. Qian,et al.  CEBPA methylation and mutation in myelodysplastic syndrome , 2015, Medical Oncology.

[13]  Thierry Fest,et al.  GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells , 2015, PLoS Comput. Biol..

[14]  J. Qian,et al.  Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome , 2014, PloS one.

[15]  J. Qian,et al.  Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. , 2014, International journal of clinical and experimental pathology.

[16]  W. Engström,et al.  Epigenetic regulation of the Igf2/H19 gene cluster , 2014, Cell proliferation.

[17]  Jun Wang,et al.  High expression of long non‐coding RNA H19 is required for efficient tumorigenesis induced by Bcr‐Abl oncogene , 2014, FEBS letters.

[18]  Anindya Dutta,et al.  The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration , 2014, Genes & development.

[19]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[20]  J. Qian,et al.  RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. , 2013, Clinical biochemistry.

[21]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[22]  Jianxin Qiu,et al.  Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression , 2013, The FEBS journal.

[23]  J. Qian,et al.  U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2012, PloS one.

[24]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[25]  Qin Chen,et al.  IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome , 2012, Annals of Hematology.

[26]  Qin Chen,et al.  Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2011, PloS one.

[27]  J. Qian,et al.  Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. , 2011, Clinical biochemistry.

[28]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[29]  Ulrich Mansmann,et al.  An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. , 2008, Blood.

[30]  F. Ferrara,et al.  Clinically useful prognostic factors in acute myeloid leukemia. , 2008, Critical reviews in oncology/hematology.

[31]  Wenhan He,et al.  Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. , 2008, Genomics.

[32]  W. Hofmann,et al.  Loss of H19 imprinting in adult T‐cell leukaemia/lymphoma , 2007, British journal of haematology.

[33]  司履生.  Cancer epigenetics , 2006 .

[34]  L. Kowalski,et al.  H19-DMR allele-specific methylation analysis reveals epigenetic heterogeneity of CTCF binding site 6 but not of site 5 in head-and-neck carcinomas: a pilot case-control analysis. , 2006, International journal of molecular medicine.

[35]  A. Seltsam,et al.  Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. , 2005, International journal of oncology.

[36]  M. Ladanyi,et al.  Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. , 2003, Human molecular genetics.

[37]  R. Weksberg,et al.  Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia. , 1997, Biochemical and biophysical research communications.

[38]  Qin Chen,et al.  MiR-675 downregulation correlates with favorable / intermediate karyotypes in de novo acute myeloid leukemia , 2016 .

[39]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[40]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[41]  A. Feinberg,et al.  Loss of imprinting in disease progression in chronic myelogenous leukemia. , 1998, Blood.